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Abstract
The viral infectivity factor, Vif, of human immunodeficiency virus type 1, HIV-1, has long been
shown to promote viral replication in vivo and to serve a critical function for productive infection
of non-permissive cells, like peripheral blood mononuclear cells (PBMC). Vif functions to
counteract an anti-retroviral cellular factor in non-permissive cells named APOBEC3G. The
current mechanism proposed for protection of the virus by HIV-1 Vif is to induce APOBEC3G
degradation through a ubiquitination-dependent proteasomal pathway. However, a new study
published in Retrovirology by Strebel and colleagues suggests that Vif-induced APOBEC3G
destruction may not be required for Vif's virus-protective effect. Strebel and co-workers show that
Vif and APOBEC3G can stably co-exist, and yet viruses produced under such conditions are fully
infectious. This new result highlights the notion that depletion of APOBEC3G is not the sole
protective mechanism of Vif and that additional mechanisms exerted by this protein can be
envisioned which counteract APOBEC3G and enhance HIV infectivity.
In contrast to most animal viruses, infection with the
human and simian immunodeficiency viruses results in
prolonged, continuous viral replication in the infected
host. Remarkably, viral persistence is not thwarted by the
presence of apparently vigorous, virus-specific immune
responses. Several factors, including the evasion of an
innate cellular anti-viral defense by HIV-1 as discussed in
a recent Retrovirology article [1], are thought to contribute
to persistent viral replication. Most notably during its
course of engendering the development of acquired
immunodeficiency syndrome (AIDS), HIV-1 mutates with
high frequency and thus avoids immune response and
intracellular defense mechanisms [2]. Interestingly, it has
been observed for several years that the genomes of HIV-
1, other retroviruses, and hepatitis B viruses show under
certain conditions a very high rate of G-to-A hypermuta-
tion [2-5]. Earlier, this mutagenic phenomenon was
attributed to the error-prone retroviral reverse tran-
scriptase together with imbalances in the available deoxy-
nucleotide pools in the cell. However, more recently a
new player has been discovered, and new studies impli-
cate the host cell cytidine deaminase APOBEC3G as
responsible for G-to-A hypermutation in viral genomes
[4,6].
APOBEC3G is a virion-encapsidated cellular protein that
deaminates dC to dU in minus-strand viral cDNA during
reverse transcription [7-10]. The uracil-containing cDNA
may then activate a cellular uracil-DNA-glycosidase caus-
ing the failure of reverse transcription. This failure is char-
acteristic of Vif-defective virus and results in the
impairment of proviral integration into the host genome
[10,11]. Furthermore, even if the reverse transcription is
completed at low efficiency and the resulting proviral
double stranded cDNA is integrated into the cellular
genome, the massive C-U conversion in the minus strand
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plus-strand cDNA [[5,7,8], and [10]]. Thus, APOBEC3G is
a member of a group of innate cellular antiviral response
factors that limit the damage inflicted by viruses to their
hosts (Figure 1).
The effects of APOBEC3G and its G-to-A deaminase activ-
ity on the survival of wild type HIV-1 vif+ virus are not
known; but, current observations are that APOBEC3G
confers a major deleterious effect to the HIV-1 genome
when the Vif protein is absent. Historically, Vif has been
known to play a dramatically important role in HIV-1
infectivity [12,13]. Vif is a basic protein of 23 kDa which
is packaged into virions and which is required in virus
producing cells during the late stages of infection to
enhance viral infectivity by 10-to-1000 folds [14-17].
HIV-1 vif-defective virus can replicate in some permissive
cells such as Jurkat and SupT1 cells, but cannot replicate
in other non-permissive cells such as macrophages, pri-
mary human T cells, and some restrictive T cell lines [18-
20]. For a very long time, it was not known what deter-
mined the difference between a permissive versus a non-
permissive cell. The answer to this long-standing puzzle
came when Michael Malim's laboratory found that non-
permissive cells contain the anti-viral cellular factor
APOBEC3G, and that the anti-viral action of APOBEC3G
is thwarted by Vif [4].
Following on the heels of that initial observation, an enor-
mous amount of effort emerged from several laboratories
directed at elucidating how Vif mechanistically counter-
acts APOBEC3G in order to protect HIV-1 (Figure 1). Sub-
sequent results showed remarkably that APOBEC3G
binds Gag nucleocapsid NC protein, and in the absence of
Vif, it is incorporated into the viral particle in close prox-
imity to the reverse transcription complex [21]. Whether
this interaction explains previous results on viral core sta-
bility or downstream effects during reverse transcription
remains unclear [22]. Additionally, it was shown that Vif
inhibited translation of APOBEC3G and/or its intracellu-
lar half-life [23-29]. In this regard, elegant biochemical
studies showed that Vif interacted with APOBEC3G as
part of a Vif-Cul5-SCF complex which led to the polyubiq-
uitination and proteasomal degradation of APOBEC3G
[30]. These latter results provided the mechanistic basis
for the current accepted paradigm whereby increased deg-
radation and/or reduced ambient level of APOBEC3G
caused by Vif hinders the incorporation of APOBEC3G
into virions. This consequently leads to an absence of
APOBEC3G during reverse transcription in the virion-
infected target cell, thereby permitting HIV-1 to replicate
more robustly (Figure 1).
Now the report by Kao et al. adds a new wrinkle to this
model by demonstrating that production of infectious
human immunodeficiency virus type 1 does not require
physical depletion of APOBEC3G in the presence of Vif
from virus-producing cells [1]. Kao's study is remarkable
for the fact that it raises the possibility of an alternative
mechanism of viral protection from APOBEC3G by Vif.
Indeed, some previous studies have shown drastic effects
of Vif on steady-state amounts of APOBEC3G while others
have found only modest effects [4,25-29]. Using confocal
microscopy, Strebel and co-workers directly compared
different methods of immunofluorescence to evaluate the
expression of APOBEC3G at the single-cell level in
absence or presence of Vif. Strikingly, depending on the
fixation method and antibodies used, the results obtained
showed variations in the number of cells which express
APOBEC3G and Vif concomitantly. Thus, it is conceivable
that direct binding of Vif to APOBEC3G may have alterred
the deaminase's conformation, covering epitopes recog-
nized by some of the antibodies used to detect
APOBEC3G. Notably, most published studies have used
APOBEC3G tagged at its N-terminus or C-terminus. Nev-
ertheless, it should be kept in mind that a possible confor-
mational change in APOBEC3G triggered by Vif-binding
may also expose hydrophobic domains that are recog-
nized by the ubiquitination and/or degradation machin-
ery [31,32]. Thus, ubiquitination of APOBEC3G may still
occur under the conditions used by Kao et al, but as dem-
onstrated by these authors no degradation of APOBEC3G
ensued. In this respect, protein ubiquitination could be
not only a signal for protein turnover, but also a signal for
cellular localization. An illustrative example of this con-
cept is the putative ubiquitination of p6 protein in which
findings by Strack et al. suggested that the engagement of
the ubiquitin conjugation machinery by L domains plays
a crucial role in the release of enveloped virus [33].
Many examples of allosteric alteration by protein-protein
interaction are reported in the literature, and further work
is necessary to evaluate possible conformational switches
induced by Vif [34-36]. Bearing this in mind, it is note-
worthy that a single amino acid substitution from D
(aspartate)128 to K (lysine) in APOBEC3G can render this
protein resistant to depletion by HIV-1 Vif [37-40]. It is
possible that this amino acid represents a direct contact
point for Vif, or that a change at this position influences
the global conformation of the enzyme. Previous studies
support the notion that this amino acid is positioned in a
protein loop and is suitable for protein contact [38]. Thus,
it is possible to speculate that Vif interaction with
APOBEC3G at this position might alter protein conforma-
tion changing its biochemical and biophysical properties
in ways that are larger than that normally expected from
altering just one amino acid position in a protein. Elegant
studies on the involvement of D128 in species specificity
of Vif to counteract APOBEC3G function are, in part, con-
sistent with this hypothesis [37-40]. Additionally, the D toPage 2 of 6
(page number not for citation purposes)
Retrovirology 2004, 1:28 http://www.retrovirology.com/content/1/1/28Schematic representation of Vif and APOBEC3G interactions during the HIV-1 replication cycleFigure 1
Schematic representation of Vif and APOBEC3G interactions during the HIV-1 replication cycle. Red arrows represent Vif 
action during the HIV-1 viral replication in non-permissive cells. Green arrows represent APOBEC3G/3F action in viral HIV-1 
Vif defective virus. Broken arrows represent inhibition of APOBEC3G activity by Vif. Question marks (?) represent unresolved 
questions about Vif and APOBEC interactions. Box1: Schematic representation of minus-strand DNA and/or viral RNA deam-
ination by APOBEC3G/3F [48]. Box2: Degradation model of APOBEC3G induced by Vif; Vif interacts with APOBEC3G as part 
of a Vif-Cul5-SCF complex resulting in the polyubiquitination and proteasomal degradation of APOBEC3G. Vif may have been 
derived from a cellular SOCS box protein that targets APOBEC 3G to the ECS ubiquitin ligase [49]. Two possible pathways of 
APOBEC3G regulation by Vif are represented.Page 3 of 6
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alter the negative electrostatic interaction of aspartate to a
positively charged amino acid which may inhibit Vif-
induced allosteric changes. Conversely, if APOBEC3G
from African green monkey, AGM, cells is considered, the
positively charged lysine 128 found in this protein cannot
interact with HIV-1 Vif but may instead do so with
SIVAGM Vif, probably by using a negatively charged pro-
tein pocket. Thus, one idea is that conformational changes
can result only from species-specific interaction between
Vif and its cognate APOBEC3G. Although this model may
be attractive, further refinements should be investigated
since the isoelectric points of HIV-1 Vif and SIVAGM Vif
are similar. Indeed, this assumption could be tested by
studies similar to those of Kao et al using APOBEC3G with
SIVAGM Vif or HIV-2 Vif, together with the role of these
proteins in the context of APOBEC3F [41,42].
In the work of Kao et al., the authors explored the possibil-
ity that the different expression systems used by them and
others could explain the discrepant results obtained on
Vif-induced APOBEC3G depletion. For this hypothesis to
hold several factors may be envisioned to interfere with
the APOBEC3G-depletion mechanism of Vif. For exam-
ple, one way to stabilize and activate p53 in cells is by
interfering either with the interaction of MDM2 and p53
or with the ability of MDM2 to target its bound p53 for
degradation [34,35]. Making a parallel between MDM2-
p53 and Vif-APOBEC3G, two mechanisms can be hypoth-
esized: one through changes in both proteins due to cov-
alent modifications, and the other through non-covalent
regulation of Vif-APOBEC3G association. In the case of
MDM2-p53, it is apparent that both mechanisms are
observed under different experimental conditions:
induced phosphorylation of p53 can attenuate the p53-
MDM2 interaction, and alternatively the human protein
p14ARF can bind to MDM2 and prevent its destruction of
p53. Interestingly, these two mechanisms of p53 regula-
tion appear to be entirely independent of each other, and
emanated through distinct signal pathways. Using this
parallel, one cautions that the findings of Kao et al. of a
lack of APOBEC3G depletion do not rule out the possibil-
ity that Vif, under different conditions, can mediate pro-
teasome dependent degradation of this deaminase [1].
Further research directions can be designed to evaluate
additional putative regulatory mechanisms of
APOBEC3G activity. For example, exposure of cells to a
variety of extracellular stimuli leads to the rapid phospho-
rylation, ubiquitination, and ultimately proteolytic degra-
dation of cellular proteins like IkappaB, which frees NF-
kappaB to translocate to the nucleus where it regulates
gene transcription [36]. NF-kappaB activation represents a
paradigm for controlling the function of a regulatory pro-
tein via ubiquitination-dependent proteolysis, as an inte-
gral part of a phosphorylation based signaling cascade.
After phosphorylation, the IKK phosphoacceptor sites on
IkappaB serve as an essential part of a specific recognition
site for E3RS (IkappaB/beta-TrCP), a SCF-type E3 ubiqui-
tin ligase, thereby explaining how IKK controls IkappaB
ubiquitination and degradation. A parallel may be envis-
aged for the regulation of Vif-induced APOBEC3G ubiqui-
tination and the consequent depletion. It was reported
recently that Vif is monoubiquitinated in the absence of
APOBEC3G [28]. In addition, when Vif is co-expressed
with APOBEC3G it is polyubiquitinated and rapidly
degraded, suggesting that co-expression accelerates the
degradation of both proteins [28,43]. Furthermore, muta-
tions of conserved phosphorylation sites in Vif impair
viral replication but do not affect APOBEC3G degrada-
tion, suggesting that Vif is important for other functions in
addition to inducing proteasomal degradation of
APOBEC3G. Whether or not phosphorylation regulates
polyubiquitination or monoubiquitination is another
open question.
Kao et al. interestingly also reported that expression of Vif
from a codon-optimized vector had a more pronounced
effect on APOBEC3G steady-state levels than wild-type Vif
from pNL-A1 [1,44]. Even though the expression level of
Vif-optimized construct is lower than wild-type, it is con-
ceivable that its intracellular half-life may be increased
affecting the quality and constancy of Vif-APOBEC3G
association. Supporting this hypothesis are results where
the authors showed a partial co-localization of Vif and
APOBEC3G which may be indicative of higher koff, typi-
cally resulting from a lower protein affinity. This type of
finding will not be observable by physical interaction
assays which employ Western blotting since only stronger
bindings are detected by such technique. Kao et al. remark-
ably demonstrated that infectious viruses are obtained in
the presence of various ratios of APOBEC3G and Vif. Nev-
ertheless, the question of whether under their conditions
APOBEC3G and/or Vif are incorporated into viral parti-
cles remains pertinent. If the deaminase is not incorpo-
rated into the viral particle, then Vif may directly or
indirectly inhibit the interaction of APOBEC3G with Gag
polyproteins in the cytoplasm [45,46]. If APOBEC3G is
included in the virion, then a direct blocking of its cyti-
dine deaminase activity by Vif can be hypothesized. To
date, a direct blocking of cytidine deaminase activity in
the cytoplasm that consequently inhibits APOBEC3G
interaction cannot be excluded. In fact, our own studies
with a bacterial deaminase system where Vif and
APOBEC3G are co-expressed show that Vif-mediated
interaction with APOBEC3G can inhibit its cytidine
deaminase activity (Santa-Marta et al; manuscript submit-
ted). These results strongly support a new mechanistic
function of HIV-1 Vif protein, complementing the model
where Vif counteracts the inhibitory effects of APOBEC3GPage 4 of 6
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pathway (Figure 1). The findings reported by Kao et al.
together with the direct effects of Vif on the activity of cyti-
dine deaminase (our work) may indicate an alternative
protective mechanism used by HIV-1 to eliminate innate
cellular immunity. Nevertheless, we cannot exclude that
HIV-1 uses Vif to exert multiple mechanisms to synergisti-
cally and more effectively inhibit the anti-viral activity of
APOBEC3G.
In conclusion, the existence of two different mechanisms
may represent two faces of the same coin, with the com-
mon goal of inhibiting APOBEC3G's anti-viral activity. As
is often the case with new findings, new questions are
posed. The link between APOBEC3G's enzymatic func-
tion, its degradation pathway, and its incorporation into
virions in the presence of Vif is certainly to require addi-
tional attention. Answers to these questions are likely to




The abbreviations used are: HIV-1, human immunodefi-
ciency virus, type 1; Vif, Viral Infectivity Factor; SIV, sim-
ian immunodeficiency virus; NC, nucleocapsid protein;
APOBEC3G, apolipoprotein B mRNA-editing enzyme cat-
alytic polypeptide-like 3G; APOBEC3F, apolipoprotein B
mRNA-editing enzyme catalytic polypeptide-like 3F
PBMC, peripheral blood mononuclear cells; Cul5, Cullin
type 5; SCF, skp1-cullin-F-box protein ligase.
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